Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck extends FoxHollow pact

October 2, 2006 | A version of this story appeared in Volume 84, Issue 40

Merck and FoxHollow Technologies will expand the scope of their collaboration on atherosclerotic plaque analysis. Merck will pay the medical device company $40 million over four years in exchange for an exclusive collaboration in specified disease areas. Merck will provide $60 million in research funding over the next three years and will pay an additional $10 million annually to extend the agreement after the initial four years. Merck will also buy $95 million in FoxHollow stock. Under a partnership announced last year, Merck has been using plaque analysis to identify biomarkers and novel targets to treat atherosclerosis.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.